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1 Introduction
From the knowledge gained from various pro-
spective studies, the incidence of respiratory dis-
tress (RDS) can be reduced by giving the mother
glucocorticoids. Today due to fear of the side
effects of such therapy, there has been a reduction
in the use of prophylaxis with corticoids. Different
substances and methods have been proposed for
induction of antenatal lung maturation including
thyroid hormones, Intralipid®, ambroxol, carni-
tine, theophylline (aminophylline) and betami-
metic agents.
2 Thyroid hormones
For a long time it has been known that there is a
connection between lung maturity and thyroid
gland metabolism [12]. Some authors found de-
creased Ts and T4 values in umbilical cord blood
samples from infants who later developed RDS
[1], In 1974 in a study with MEINHOLD, we found
a correlation between amniotic fluid lecithin and
the reverse Ta level [11].
Studies performed on rats, rabbits and lambs have
shown that thyroxine stimulates the phospholipid
production in the fetal lung, where Ts and T4
receptors can be found. Since the transfer of Ts
and T4 through the placenta is very minimal, the
thyroxine has to be given intra-amniotically or into
the fetus.
In human beings intra-amniotic instillation of thy-
roxine should increase lung maturity and lower
the number of cases of RDS [10]. In order to
measure the effectiveness of surfactant stimulation
with thyroxine, 22 pregnant patients with a gesta-
tional age of under 35 weeks were studied. The
concentration of thyroxine and lecithin in amni-
otic fluid and in maternal and fetal serum were
determined after giving an intra-amniotic dosage
of 500 g levothyroxine [2]. The hormone determi-
nations were performed radioimmunologically
and the lecithin was determined enzymatically.
Groups were drawn up according to the interval
between the instillation of T4 in the amniotic fluid
and fresh normal amniotic fluid collected when
the membranes ruptured at the start of labor. In
this way a limit of 5 days was empirically created
in 12 cases the interval was the same or less than
5 days (Group A), in the remaining 10 cases the
time interval was more than 5 days (Group B).
Amniotic fluid: The mean value of the T4 concen-
tration rises in Group A 18 times as the control
group. In Group B the concentration is not dif-
ferent from the original level (figure 1). The mean
value of rTs after T4 injections into the amniotic
fluid points to a significant increase which is about
13 times normal. In Group B no difference can
be seen.
Umbilical cord blood: While the T4 and rTs concen-
trations in Group A and B are significantly dif-
ferent, the T3 concentrations are similar in both
groups (figure 2). Similar results to the increase
in T4 in umbilical cord blood were reported by
RIDDICK et al in 1979 [14].
Maternal serum: The concentrations of T4, Ta and
rTs were measured before, 30 minutes after and
24 hours after T4 injections into the amniotic fluid
(figure 3). No significant changes were to be seen
in maternal blood.
1987 by Walter de Gruyter & Co. Berlin · New York











10 ·• ι ή l
rT3
(ng/ml)






Figure 1. Median, maximum and minimum levels of T4
and rTs in amniotic fluid before thyroxine dosage (1)
and the start of labor, either in a time interval of exactly
or less than 5 days between dosage and labor (2, Group












Figure 2. Median, maximum and minimum levels of T4,
Ta and rTs in umbilical cord vein blood in Group A
(time interval between T4-Dosage and labor equal to or















Figure 3. Median, maximum and minimum levels of T4,
Ts and rTs before thyroxine dosage (1), 30 minutes later
(2) and 24 hours (3) after thyroxine dosage in maternal
serum.
The results must be interpreted such that the T4
injection into the amniotic fluid leads to an in-
crease of T4 in the fetal blood. This clearly demon-
strates that the T4 injected into the amniotic fluid
is absorbed by the fetus. However in the group
where the interval between injection and delivery
was more than 5 days, we observed that the T4
level had become normal again.
Thyroid hormones absorbed by the fetus will exer-
cise their effect on various fetal organs. As an
expression of the cardial effect of the thyroid
hormones after thyroxine injection we found a
moderate fetal tachycardia in 5 cases two days
after the injection.
It seems that there is no paraplacental passage of
the T4 injected into the maternal blood.
In addition to the hormone examination we also
tested the lecithin concentrations in amniotic fluid
before and after T4 injections; we observed a sig-
nificant increase of the median values from 3.5
mg/100 ml to 5.2 mg/100 ml after injection. The
mean value in Group A was 5.6 mg/100 ml and
in Group B 4.3 mg/100 ml. The induction of
surfactant production by means of thyroxine
probably creates a reversible effect mechanism.
In this connection RDS diagnosed by neonatolo-
gists is important: While in our group about 8
J. Perinat. Med. 15(1987)
Dudenhausen, Prevention of neonatal RDS 455
cases of RDS were to be expected, this diagnosis
had only been made in 2 cases.
Therapy with thyroid hormone is possibly medi-
ated through TRH, which can be administered to
the patient intravenously and affects the infant
through the placenta [13]. This type of lung matu-
ration induction is still only in the testing stage at
the moment.
There are suggestions that combined therapy with
thyroid hormones and glucocorticoids has a
marked effect on fetal lung maturity; however
definite guidelines have not been drawn up [16].
Too little is known at present about the side effects
of treatment with thyroid hormones or their anal-
ogous. Changes in growth or cerebral dys-
functions due to hyperthyroidism are possible.
The risks involved in giving thyroxine with regard
to increase in oxygen output are not understood
although this increase does not necessarily have
to be the same in all organs. The question of
increased oxygen output of T4 injection would be
of particular importance when dealing with fetuses
with respiratory placental insufficiency.
3 Intra-amniotic application of Intralipid®
OBERHEUSER and KLINK examined the possibility
of stimulating surfactant formation by supplying
a substrate of lecithin [6]. As the lecithins are
supposedly not absorbed by the placenta, they
have to be given intra-amniotically. They are able
to prove in tests on rabbits, dwarf pigs and also
on human subjects, that the lecithin is swallowed
by the fetus and is absorbed in the intestine. The
metabolism takes place in the liver. After resyn-
thesis part of the lecithin is to be found in the
pulmonary alveoli.
In the meantime the group has been able to prove
the Intralipid® effects in tissue cultures of the
human fetal lung, too.
On the basis of the mentioned observations they
carried out intra-amniotic injection of Intralipid®
in patients with premature labor between the
26th —36th week of gestation. They applied 60
ml Intralipid® in exchange for aspirated amniotic
fluid which was used to determine the L/S ratio.
In all cases there was no evidence of premature
rupture of membranes.
The frequency and degree of RDS in premature
babies with a birth weight under 2500 g during
the past 7 years in the University Hospital of
Lübeck were evaluated in order to assess the effi-
cacy of Intralipid® therapy.
Table I shows the frequency and degree of RDS
in premature infants after Intralipid® application,
corticosteroid therapy in the form of 2 50 mg
Solu-Decortin® I.V. within the first 24 hours and
cases without previous induction of fetal lung
maturity.
Statistical significance of the efficacy of Intrali-
pid® injection cannot be determined due to the
small number of cases and the large difference in
the individual groups. It should be pointed out,
that no death was observed, and only one case
with severe RDS was recorded. As far as mortality
is concerned, corticosteroid therapy, as expected,
is compared to untreated cases.
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4 Ambroxol
Clinical studies and experiments on animals have
been performed for years in order to prove the
effect of ambroxol on lung maturation. The effect
is supposed to be dependent upon stimulation of
the secretory cells in the alveolar epithelium. This
mechanical effect has not been definitely clarified.
Earlier clinical studies — some involving a smaller
dosage than today — did not provide positive
results [9]. In 1982 WALTER and coworkers, in a
larger double-blind study, showed that in patients
with a gestational age of 33 to 36 weeks, who had
been given 1000 g ambroxol intravenously over a
period of 5 days, the incidence of RDS was lower
[17]. They did not find an effect before the 32nd
week of gestation.
A German-Austrian multicenter double-blind
study of 190 children examined the effects of beta-
methasone and ambroxol for antenatal pulmon-
ary maturity induction between the 28th and 36th
week of gestation. They showed that the same
results were achieved with ambroxol as with beta-
methasone [15]. Ambroxol would have an advan-
tage due to few long-term side effects. The disad-
vantage of the therapy is that it requires five
days. It is not always possible to treat a patient
effectively with tocolytic drugs for 5 days or to
postpone a premature delivery.
intramitochondrial transport and regulation of
the beta-oxydation of long chain fatty acids. The
synthesis of palmitic acids, their insertion into
mitochondria! phospholipids and also the forma-
tion of lecithin via methylation could be stimu-
lated by carnitine. In animal experiments, LOHNIN-
GER and coworkers were able to show that the
combination of carnitine and betamethasone due
to their different mechanisms, leads to a larger
increase of phosphatidylcholin in the lung of the
fetal rat than single dosages of the two substances
[8]. Comparable results were found in the carni-
tine/thyroxin group.
6 Aminophylline
Animal studies of the effect of aminophylline on
pulmonary maturity induction have been hopeful.
HAJIGEORGIOU and coworkers have reported in a
prospective study of a lessened incidence of RDS
after treating mothers with aminophylline [5]. The
effect is neither absolute, nor have the side effects
been studied intensively. It is assumed that ami-
nophylline increases the tissue content of cyclic
AMP (cAMP) by inhibition of cAMP-phosphod-
iesterase. An increase in phospholipid synthesis
takes place through the increased concentration
of cAMP in the alveolar cells.
5 Carnitine
Carnitine is known to be an important factor
for breaking down fatty acids in humans. With
increased gestational age, a rise in the carnitine
content was measured in the fetal lung of the rat.
The carnitine dosage given to the pregnant rat
caused a rise in the carnitine level in the fetal lung
[7].
The suggestion that pulmonary maturity induc-
tion could be achieved with carnitine assumes
that carnitine encourages surfactant formation by
7 Betasympathomimetic agents
Betasympathomimetic agents are used to inhibit
uterine contractions. Retrospective studies have
shown that when used for a short period they
decrease the incidence of RDS [4]. Possibly these
agents also produce changes in the cAMP content
and increase adenylcyclase or increase the release
of surfactant from the lamellar bodies. The impor-
tance of betasympathomimetics is dependent on
the amount given and the duration of therapy and
has not been clarified definitely [3].
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Zusammenfassung
Alternativen zur antenatalen Glukokortikoid-Behandlung
zur Vermeidung des Membransyndroms
Neben der Lungenreifeförderung mit Kortikoiden wer-
den verschiedene Substanzen zur antenatalen Lungenrei-
feförderung benutzt, z. B. die Schilddrüsenhormone, In-
tralipid®, Ambroxol, Carnitin, Theophyllin (Amino-
phyllin) und Betasympathomimetika.
Schilddrüsenhormone: Verschiedene Autoren haben Zu-
sammenhänge zwischen der Lungenreife und dem
Schilddrüsenstoffwechsel nachgewiesen. Tierexperi-
mente haben gezeigt, daß Thyroxin die Phospholipidsyn-
these in der fetalen Lunge steigert. Beim Menschen ver-
mehrt intraamnial appliziertes Thyroxin die Lungenreife
und senkt die Rate des Membransyndromes. Um die
Effektivität der Surfactant-Stimulation mit Thyroxin zu
prüfen, haben wir bei 22 Schwangeren mit einem
Schwangerschaftsalter unter 35 Wochen die Konzentra-
tion an Schilddrüsenhormonen im Fruchtwasser, im
mütterlichen und fetalen Plasma nach intraamnialer
Gabe von 500 g L-Thyroxin untersucht. Die Ergebnisse
zeigen, daß das Thyroxin vom Feten resorbiert wird. In
der Gruppe, in der zwischen Injektion und Geburt mehr
als 5 Tage liegen, sahen wir eine Normalisierung des
Thyroxin. Die Schilddrüsenhormone haben Effekte an
verschiedenen fetalen Organen, so z. B. am Herzen,
sichtbar an einer mittelgradigen Tachykardie in einigen
Fällen zwei Tage nach der Injektion. Neben den Hor-
monbestimmungen haben wir vor und nach der Thyro-
xin-Injektion die Lezithin-Konzentration im Fruchtwas-
ser gemessen; wir sahen einen signifikanten Anstieg.
Allerdings scheint die Surfactant-Produktion durch Thy-
roxin ein reversibler Vorgang zu sein.
Intralipid®: Eine Autorengruppe prüfte die Stimulation
der Surfactant-Bildung durch die intraamniale Gabe von
Lezithinen. Sie wies tierexperimentell und auch am Men-
schen nach, daß das Lezithin vom Feten geschluckt und
im Darm resorbiert wird. Nach Metabolisation in der
Leber und Resynthese findet sich das Lezithin wieder in
der Alveole. Auf diese Grundlage wurden Frauen mit
vorzeitigen Wehen zwischen der 26. und 36. Woche mit
60 ml Intralipid® intraamnial behandelt. In der Gruppe
fand sich kein Todesfall, nur ein Fall mit schwerem
Membransyndrom.
Ambroxol: Der Effekt des Ambroxol auf die Lungenreife
wird in der Stimulation der sekretorischen Pneumozyten
des Alveolarepithels gesehen, allerdings ist dieser Vor-
gang nicht definitiv geklärt. 1982 wurde eine größere
Doppelblindstudie publiziert, die eine Minderung der
Membransyndrom-Rate bei Patientinnen zwischen der
32. und 36. Woche zeigte, denen 1000 g Ambroxol intra-
venös über fünf Tage gegeben worden war. Unter der
32. Woche fand sich keine Wirkung.
Carnitin: Mit ansteigendem Schwangerschaftsalter ist ein
ansteigender Gehalt der fetalen Rattenlunge an Carnitin
meßbar. Außerdem steigert die Carnitingabe an schwan-
gere Ratten den Carnitin-Gehalt der fetalen Lunge.
Aminophyllin: In einer prospektiven Studie zeigte sich
eine niedrigere Membransyndrom-Rate Aminophyllin-
behandelter Mütter. Der Effekt ist noch nicht vollkom-
men gesichert, außerdem sind die Nebenwirkungen noch
nicht intensiv untersucht.
Betasympathomimetika: Retrospektive Untersuchungen
haben die Minderung der Membransyndrom-Rate nach
Kurzzeitgabe von Betasympathomimetika belegt.
Schlüsselwörter: Ambroxol, Aminophyllin, Betasympathomimetika, Carnitin, Intralipid®, Lungenreifeförderung,
Prävention, RDS, Schilddrüsenhormone.
Resume
Alternatives au traitement glucocortico'ide antenatal pour
la prevention du SDR chez le nouveau-ne
Outre les cortico'ides, diverses substances et methodes
sont utilisees pour stimuler la maturation pulmonaire
antenatale, ä savoir les hormones thyro'idiennes, FIntrali
pid®, Fambroxol, la carnitine, la theophylline (amino-
phylline) et les betamimetiques.
Hormones thyroidiennes: On a su a partir de certains
auteurs qu'il existait des relations entre la maturite pul-
monaire et le metabolisme de la glande thyro'ide. Des
etudes ont ete realisees chez le rat, le lapin et Fagneau,
etudes qui ont montre que la thyroxine stimule la pro-
duction de phospholipides dans le poumon foetal. Dans
Fespece humaine des instillations intra-amniotiques de
thyroxine augmenteraient la maturite pulmonaire et di-
minueraient le nombre de cas de syndrome de membra-
nes hyalines. Aim de faire le bilan de Fefficacite de la
Stimulation du surfactant par la thyroxine chez 22 fem-
mes enceintes avec un äge gestationnel inferieur ä 35
semaines, nous avons etudie revolution de la concentra-
tion en hormone thyro'idienne dans le liquide amnioti-
que, dans le sang materael et foetal apres administration
intra-amniotique de 500 g de levothyroxine. Les resul-
tats sont ä interpreter car la T4 injectee dans le liquide
amniotique est resorbee par le foetus.
Toutefois, dans le groupe pour lequel Fintervalle entre
Pinjection et Faccouchement a ete superieur ä 5 jours,
nous avons observe que les taux de T4 s'etaient de
nouveau normalises. Les hormones thyroi'diennes resor-
bees par le foetus exercent leurs effects sur divers organes
foetaux. Comme expression de Feffet cardiaque, des hor-
mones thyro'idiennes apres injection de thyroxine, nous
avons trouve une tachycardie foetal moderee, dans quel-
ques cas, deux jours apres Finjection. En complement
du bilan hormonal, nous avons egalement doses les
concentrations de lecithine dans le liquide amniotique
avant et apres injections de T4. Nous avons observe une
augmentation significative des valeurs moyennes apres
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injection. L'induction de la production de surfactant au
moyen de la thyroxine cree probablement un mecanisme
reversible.
Intralipid®: Dans la litterature, un groupe de recherche
a examine la possibilite de stimuler la formation de
surfactant grace a l'apport d'un Substrat de lecithine.
Comme les lecithines ne sont pas supposes etre absorbes
par le placenta, il faut les administrer en intra-amnioti-
que. Les auteurs ont pu prouver par des tests chez
Panimal et egalement chez des sujets humains que la
lecithine est deglutie par le foetus et absorbee dans 1'intes-
tin. La metabolisation s'effectue dans le foie. Apres
resynthese, une partie de la lecithine est retrouvee dans
les alveoles pulmonaires. Sur la base des observations
mentionnees, ils ont realise Padministration intra-amnio-
tique de 60 ml d'Intralipid® chez des patients avec un
accouchement premature entre la 26e et la 36e semaine
de gestation. II faut insister sur le fait que le taux de
mortalite a ete nul et que seul un cas a presente un SDR
severe.
Ambroxol: L'effet de l'ambroxol sur la maturation pul-
monaire est suppose dependre d'une stimulation des
cellules secretaires de repithelium alveolaire. Toutefois,
cet effet mecanique n'a pas ete definitivement clarifie.
En 1982 une etude en double aveugle plus importante a
ete public; eile montre que chez les patientes avec un
äge gestationnel de 33 ä 36 semaines, auxquelles on a
injecte 1000 g d'ambroxol par voie intra-veineuse sur
une periode de 5 jours, l'incidence du syndrome des
membranes hyalines est plus faible. Neanmoins, on n'a
pas trouve d'effet avant la 32e semaine de gestation.
Carnitine: Avec l'elevation de l'äge gestationel, on a
mesure une elevation de la teneur en carnitine dans le
poumon foetal chez le rat et l'apport de carnitine ä la
rate gravide entraine une elevation du taux de carnitine
dasn le poumon foetal.
Aminophylline: II a ete vu dans une etude prospective une
minoration de l'incidence du syndrome de membranes
hyalines apres traitement maternel par aminophylline.
L'effet n'est pas certain d'une part et d'autre part les
effects secondaires n'ont pas ete etudies de facon intensi-
ve.
Betamimetiques: Des etudes retrospectives ont montre
que lorsqu'on les utilise pendant une courte periode,
ils diminuent l'incidence du syndrome des membranes
hyalines.
Mots-cles: Ambroxol, amelioration de la maturation pulmonaire, aminophylline, betamimetiques, carnitine, Intra-
lipid®, prevention, SDR.
References
[1] DHAMIREDDY R, YF SMITH, M HAMOSH, DK MUL-
LON, JW SCANLON, P HAMOSH: Respiratory distress
syndrome in the newborn: Relationship to serum
prolactin, thyroxine, and sex. Biol Neonate 43
(1983) 9
[2] DUDENHAUSEN JW: Wirkungen der intraamnialen
Thyroxingabe auf den Feten. Geburtshilfe Frauen-
heilkd 44 (1984) 777
[3] DUDENHAUSEN JW, G KYNAST, A-M LANGE-LIND-
BERG, E SALING: Influence of long-term betamimetic
therapy on the lecithin content of amniotic fluid.
Gynecol Obstet Invest 9 (1978) 205
[4] GERNER R: Untersuchungen zur Beeinflussung der
Lezithinsynthese in der fetalen Lunge durch Toko-
lytika. In: SCHMIDT E, JW DUDENHAUSEN, E SA-
LING: Perinatale Medizin Band VII. 8. Deutscher
Kongreß für Perinatale Medizin 1977. Thieme,
Stuttgart 1978
[5] HADJIGEORGIOU E, S KITSIUO, A PSAROUDAKIS, C
SEGOS, D NICOLOPOULOS, D KASAKARELIS: Antepar-
tum aminophylline treatment for prevention of the
respiratory distress syndrome in premature infants.
Am J Obstet Gynecol 135 (1979) 257
[6] KLINK F, L v KLITZING, D KLEINBAUER, H KUNKEL-
MANN, F OBERHEUSER: Prenatale respiratory distress
syndrodrome prophylaxis through intraamniotic
application of Intralipid®. 10th European Congress
of Perinatal Medicine, Leipzig, August 12 — 16,
1986
[7] LOHNINGER A, HP KRffiGLSTEINER, A NlKOFOROV,
W ERHARDT, M SPECHER, G MARTIN, E KAISER:
Comparison of the effects of betamethasone and
L-carnitine on dipalmitoyl phosphatidylcholine
content and phosphatidylcholine specien composi-
tion in fetal rat lungs. Pediatr Res 18 (1984) 1246
[8] LOHNINGER A, HP KRIEGLSTEINER, H SALZER, E
VYTISKA-BINSTORFER, W RIEDL, W ERHARDT: Stud-
ies on the effects of betamethasone, L-carnitine and
betamethasone-L-carnitine combinations on the
dipalmitoyl-phosphaditylcholine content and phos-
phatidylcholine species composition in foetal rat
lungs. J Clin Chem Clin Biochem 24 (1986) 361
[9] LORENZ U, R RÜTTGERS, F KUBLI: Klinische Dop-
pelblindstudie zur Frage der antepartalen Lungen-
reifung unter Ambroxol. Atemwegs- u. Lungen-
krankheiten 4, Suppl l (1978) 30
[10] MASHIACH S, G BARKAI, J SACK, E STERN, M BRISH,
B GOLDMAN, DM SERR: The effect of intra-amniotic
thyroxine administration on fetal lung maturity in
man. J Perinat Med 7 (1979) 161
[11] MEINHOLD H, JW DUDENHAUSEN, KW WENZEL, E
SALING: Amniotic fluid concentrations of 3, 3', 5'-
triiodothyronine (reverse Ts), 3, 3/-diiodothyronine,
3, 5, 3/-tri-iodothyronine (Ta) and thyroxine (T4) in
normal and complicated pregnancy. Clin Endocri-
nol 10 (1979) 355
[12] MORISHIGE WK, DL GUERNSEY: Triiodothyronine
receptors in rat lung. Endocrinology 102 (1978)
1628
J. Perinat. Med. 15(1987)
Dudenhausen, Prevention of neonatal RDS 459
[13] MORLEY JE, RA BASHORE, A REED, HE CARLSON,
JM HERSHMAN: Thyrotropin-releasing hormone
and thyroid hormones in amniotic fluid. Am J
Obstet Gynecol 134 (1979) 581
[14] RIDDICK DH, JA MASLAR, AA LUCIANO, JR RAYE:
Thyroxine uptake and metabolism by fetal sheep
after intra-amniotic thyroxine injection. Am J
Obstet Gynecol 133 (1979) 618
[15] SALZER H, H WEIDINGER, G SIMBRUNER, E VYTISKA-
BINSTORFER: Ambroxol versus Betamethason zur
Förderung der antepartalen Lungenreife — eine
multizentrische Studie. Z Geburtshilfe Perinatol
190 (1986) 49
[16] TORDAY JS, KE Dow: Synergistic effect of triiodo-
thyronine and dexamethasone on male and female
fetal rat lung surfactant synthesis. Dev Pharmacol
Ther 7 (1984) 133
[l WAUER RR, G SCHMALISCH, K MENZEL, M
SCHRÖDER, K MÜLLER, R ULLER, G METHFESSEL,
U SITKA, E KOEPKE, CH PLATH, C SCHLEGEL, M
BÖTTCHER, I KOPPE, U FRICKE, K SEVERIN, R JA-
COBI, W SCHMIDT, GK KINKEL, I NITZ, D KUNZE,
G REICHMANN, B LACHMANN, K LAMPE, EL
GRAUEL: The antenatal use of ambroxol (bromhex-
ine metabolite VIII) to prevent hyaline membrane
disease: A controlled double-blind study. Biol Res
Pregnancy 3 (1982) 84




J. Perinat. Med. 15 (1987)
Receptor Mediated
Antisteroid Action
Editor M. K. Agarwal
1987.17 cm χ 24 cm. VIII , 524 pages. Numerous illustrations.
Hardcover. DM 298,-; approx. US $ 175.00 ISBN 311 011355 4
This volume groups together latest conceptual developments and
ongoing designs for antagonists in all groups of steroid hormones at
the pharmacological, biochemical, and clinical level. New biochemical
and immunocytochemical approaches to probe the nature of
receptor localization and function have been reviewed as well. The
influence of antisteroids in modifying behaviour, steroid hormones in
insects, and the approach of idiotype selection to study hormone
action, have been included to give the volume even wider appeal.
All authors are active in the fields in which they have contributed and
the collection of papers by experts under one single cover provides
the opportunity to glance at material one would not otherwise read. It
is certain that this multidisciplinary approach will lead to the cross
fertilization of ideas so necessary for further conceptual and practical
effort to dissect the receptor and use it to alleviate disease.




de Cruyter · Berlin · New York
